Drugs / KITE-363
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07304154 | Apr 2026 → Jun 2029 expected | multiple sclerosis, myasthenia gravis, polyneuropathy, inflammatory demyelinating, chronic | Kite, A Gilead Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07038447 | Jul 2025 → Jul 2029 expected | idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus, systemic sclerosis | Kite, A Gilead Company | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04989803 | Oct 2021 → Feb 2030 expected | B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-363 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038447 ↗ |
| Modality | Cell therapy | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |
| Route | Intravenous | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |